Novartis shareholders approved 25% dividend increase
- Details
- Category: Novartis
Novartis shareholders have followed the Board of Directors' recommendations for all proposed resolutions at the Group's Annual General Meeting. These included a 25% increase in the dividend payment for 2008, the rejection of the introduction of a consultative vote on the remuneration report and the election of William Brody, M.D., Ph.D. as a new Board member.
Abbott Successfully Completes Tender Offer for Shares of Advanced Medical Optics
- Details
- Category: Abbott
Abbott today announced the successful completion of the tender offer by its wholly owned subsidiary Rainforest Acquisition Inc. to purchase all of the outstanding shares of common stock of Advanced Medical Optics (AMO). The tender offer expired at midnight Eastern time on Tuesday, Feb. 24, 2009, and was not extended.
Pfizer Discontinues Development of Two Phase 3 Compounds
- Details
- Category: Pfizer
Pfizer Inc has announced that, following a review of the development and commercial portfolios in the Primary Care Business Unit, it is terminating Phase 3 development programs for the investigational compounds esreboxetine for fibromyalgia and PD 332,334 for generalized anxiety disorder (GAD).
Nycomed reports a satisfactory 2008
- Details
- Category: Nycomed
For Nycomed the twelve months of 2008 have been satisfactory and most of the markets performed well and met expectations. Key products developed strongly, with the exception of Pantoprazole sales in the United States and Canada, which is due to âat-riskâ launch and generic competition, respectively. The company's integration restructuring showed its full cost-savings effect in 2008.
Schering-Plough announces collaboration with World Health Organization
- Details
- Category: Business
Schering-Plough Corporation (NYSE: SGP) has announced a license agreement between Nobilon, Schering-Plough's human vaccine business unit, and the World Health Organization (WHO) to provide access to pandemic influenza vaccine manufacturing technology to developing countries.
Encouraging results support further development of Almirall's long-acting beta-agonist (LABA)
- Details
- Category: Clinical Trials
Further to the results of prior studies published last year, Almirall, the international pharmaceutical company based in Spain, announced new Phase II multi-dose study results demonstrating that its novel once-daily, inhaled, long-acting beta-agonist (LABA) -LAS100977-, for the treatment of bronchoconstriction in asthmatic patients, shows fast-acting and 24-hour efficacy, as well as a good safety and tolerability profile in patients during multiple dose administrations.
Abbott Receives European Commission Clearance on Acquisition of Advanced Medical Optics
- Details
- Category: Abbott
Abbott (NYSE: ABT) has received merger control clearance from the European Commission for its acquisition of Advanced Medical Optics (AMO) through a cash tender offer for the outstanding shares of common stock of AMO. The European Commission approved the transaction without conditions.
More Pharma News ...
- The safety of patients is of utmost importance to Merck
- GSK initiates phase III programme for novel type 2 diabetes medication, Syncria® (albiglutide)
- FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab
- Bristol-Myers Squibb Foundation to Bridge Gaps in Hepatitis C Awareness, Prevention and Care
- Immune-boosting effect of Pegasys provides patients with the chance for a clinical cure
- New England Journal of Medicine publishes results from the landmark ATHENA trial
- Sandoz receives European Commission approval for biosimilar filgrastim